Autolus Therapeutics plc (AUTL)
| Previous close | 3.9300 |
| Open | 4.0900 |
| Bid | 3.9400 x 200 |
| Ask | 3.9600 x 100 |
| Day's range | 3.9200 - 4.2100 |
| 52-week range | 2.0100 - 7.4500 |
| Volume | |
| Avg. volume | 1,555,252 |
| Market cap | 1.072B |
| Beta (5Y monthly) | 2.03 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.2000 |
| Earnings date | 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 10.69 |
GlobeNewswireAutolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
LONDON, May 14, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the online publication of three abstracts submitted to the European Hematology Association (EHA) Congress, to be held June 13-16, 2024. Oral presentation: Title: obecabtagene autoleucel in adult relapsed/refractory B Cell acute lymphoblastic leukemia: Survival and potential impact of CAR-T cell persist
- GlobeNewswire
Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call
LONDON, May 13, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it intends to file a Form 12b-25, Notification of Late Filing, with the U.S. Securities and Exchange Commission later this week with regard to its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 (the “Q1 2024 10-Q”). Form 12b-25 will allow the Company an automatic extension of f
Simply Wall St.Recent 13% pullback isn't enough to hurt long-term Autolus Therapeutics (NASDAQ:AUTL) shareholders, they're still up 157% over 1 year
Autolus Therapeutics plc ( NASDAQ:AUTL ) shareholders might be rather concerned because the share price has dropped 33...
